Skip to main content

Client News

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

27th October 2021

Adocia announces 2021 third quarter financial results and a financing of €7 million through the issuance of convertible bonds subscribed by European investors and ordinary shares subscribed by Gérard Soula, Adocia co-founder

27th October 2021

Marinomed partners with Perrigo to distribute virus-blocking Carragelose nasal spray in Scandinavia and France

27th October 2021

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases

26th October 2021

Andera Partners supports Exciva in a Series A to fight Alzheimer’s disease

26th October 2021

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

26th October 2021

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy

20th October 2021

InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19

19th October 2021

MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

13th October 2021

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

12th October 2021